Zobraziť v EDS

Effect of Abaloparatide on Bone Microarchitecture Assessed by Trabecular Bone Score in Women With Osteoporosis: Post Hoc Analysis of ACTIVE and ACTIVExtend

Uložené v:
Podrobná bibliografia
Názov: Effect of Abaloparatide on Bone Microarchitecture Assessed by Trabecular Bone Score in Women With Osteoporosis: Post Hoc Analysis of ACTIVE and ACTIVExtend
Autori: Felicia MD Cosman, Didier PhD Hans, Enisa PhD Shevroja, Yamei PhD Wang, Bruce MD Mitlak
Zdroj: Journal of bone and mineral research, vol. 38, no. 4, pp. 464-470
Informácie o vydavateľovi: Oxford University Press (OUP), 2020.
Rok vydania: 2020
Predmety: Female, Humans, Alendronate/pharmacology, Alendronate/therapeutic use, Cancellous Bone/diagnostic imaging, Osteoporotic Fractures/drug therapy, Spinal Fractures/drug therapy, Osteoporosis/drug therapy, Bone Density, Bone Density Conservation Agents/pharmacology, Bone Density Conservation Agents/therapeutic use, Lumbar Vertebrae, Osteoporosis, Postmenopausal/drug therapy, ANABOLICS, ANALYSIS/QUANTITATION OF BONE, CLINICAL TRIALS, DXA, OSTEOPOROSIS, Alendronate, Bone Density Conservation Agents, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Cancellous Bone, Spinal Fractures, Osteoporosis, Osteoporotic Fractures, Osteoporosis, Postmenopausal
Popis: Although bone mineral density (BMD) is a predictor of fracture, many fractures occur in women with T-scores > −2.5. Bone microarchitecture, assessed by trabecular bone score (TBS), predicts fracture risk independent of BMD. We evaluated whether abaloparatide improves TBS and whether TBS trends were associated with vertebral fracture risk reduction. Women with osteoporosis randomized to abaloparatide or placebo for 18 months (ACTIVE), followed by alendronate for 24 months (ACTIVExtend), with evaluable TBS, were included in this post hoc analysis (N = 911). TBS was calculated from spine BMD scans using an algorithm adjusted for tissue thickness (TBSth) at baseline, 6, 18, and 43 months. Mean increments in TBSth from baseline within and between treatment groups, proportion of women with TBSth increments above least significant change (LSC) and proportion with degraded TBSth ( Abstract Mean TBSth (95% CI) percent change over time. Both ABL and PBO ended at 18 months (solid lines); at 19 months, all subjects started ALN for 24 months (dotted lines). *p
Druh dokumentu: Article
Popis súboru: application/pdf
Jazyk: English
ISSN: 1523-4681
0884-0431
DOI: 10.1002/jbmr.4764
Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/36588166
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_210A7E8BE4274
https://serval.unil.ch/resource/serval:BIB_210A7E8BE427.P001/REF.pdf
https://serval.unil.ch/notice/serval:BIB_210A7E8BE427
Rights: CC BY
Prístupové číslo: edsair.doi.dedup.....3a393c6696851e22b8aa0622b680d93b
Databáza: OpenAIRE
Popis
Abstrakt:Although bone mineral density (BMD) is a predictor of fracture, many fractures occur in women with T-scores > −2.5. Bone microarchitecture, assessed by trabecular bone score (TBS), predicts fracture risk independent of BMD. We evaluated whether abaloparatide improves TBS and whether TBS trends were associated with vertebral fracture risk reduction. Women with osteoporosis randomized to abaloparatide or placebo for 18 months (ACTIVE), followed by alendronate for 24 months (ACTIVExtend), with evaluable TBS, were included in this post hoc analysis (N = 911). TBS was calculated from spine BMD scans using an algorithm adjusted for tissue thickness (TBSth) at baseline, 6, 18, and 43 months. Mean increments in TBSth from baseline within and between treatment groups, proportion of women with TBSth increments above least significant change (LSC) and proportion with degraded TBSth ( Abstract Mean TBSth (95% CI) percent change over time. Both ABL and PBO ended at 18 months (solid lines); at 19 months, all subjects started ALN for 24 months (dotted lines). *p
ISSN:15234681
08840431
DOI:10.1002/jbmr.4764